Study of danicamtiv for genetic and familial dilated cardiomyopathy
Part of Heart & circulation clinical trials.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dilated cardiomyopathy caused by a genetic change in MYH7, TTN, or another known gene, or it runs in your family
- You have heart failure symptoms like shortness of breath or fatigue (NYHA class II to IV) that have been stable for at least 1 month
- Your heart's left ventricle is slightly enlarged and your heart's pumping strength (LVEF) is 45% or less
- You are already taking the best standard heart failure medications for at least 4 weeks
- Your dilated cardiomyopathy is not caused by things like drug abuse, sarcoidosis, or amyloidosis
- You can do an exercise test on a bike or treadmill and your peak oxygen uptake is 80% or less of normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
This study tests whether a personalized treatment approach can improve heart function in people with dilated cardiomyopathy (a condition where the heart becomes enlarged and weak). It focuses on patients who still have low heart function despite standard medications.
This trial tests whether combining modern heart failure medications with an implantable defibrillator (ICD) can reduce the risk of dangerous heart rhythms and improve survival in people with dilated cardiomyopathy. It focuses on those with a weak heart pump and specific scarring seen on MRI.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This trial tests whether candesartan (a blood-pressure medicine) can delay or prevent heart muscle weakening in people who carry a disease-causing dilated cardiomyopathy gene variant but still have fairly strong heart pumping. Participants are randomly assigned to candesartan or a placebo to see which one keeps the heart healthier over time.
Hear when a new Symptomatic Genetic Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.